An EPCS program is failing when prescribing rules exist on paper but are not consistently enforced, when prescribers can bypass required checks, or when the workflow is so awkward that users avoid it. A strong warning sign is the gap between policy and execution, especially if clinicians can send controlled substance prescriptions without completing the required verification steps.
How to spot EPCS failure before it turns into routine workarounds
The clearest sign of failure is a mismatch between the policy and the actual workflow. If EPCS controls exist but clinicians can still move prescriptions through with little friction, little verification, or inconsistent enforcement, the program is functioning as a paper control rather than an operational safeguard. The warning is not only noncompliance, but normalisation of bypasses.
A second sign is repeated reliance on exceptions. When users are forced into manual overrides, shared access patterns, or “temporary” fixes to get prescriptions out, the control design is no longer aligned to clinical reality. At that point, the program is measuring tolerance for exceptions instead of proving controlled substance prescriptions are being handled securely.
A third sign is weak visibility. If teams cannot easily tell who prescribed, who approved, what step failed, or where the workflow broke down, then the program may be technically deployed but operationally unverifiable. That makes it hard to distinguish isolated user frustration from a systemic control gap.
Where the workflow usually breaks
EPCS failure often shows up at the handoff points: identity proofing, multifactor verification, signing steps, or system-to-system integrations. The workflow may appear compliant in design, but one weak link lets clinicians complete the action without completing the intended verification path. That is especially concerning when the same path works inconsistently across locations, devices, or user populations.
The most important practical distinction is between inconvenience and control erosion. A cumbersome process does not automatically mean the program is failing, but if users start avoiding the intended path because it is slow, unreliable, or confusing, the control is already losing authority. In practice, poor usability becomes a security issue when it drives predictable workarounds.
When the issue is identity or access related, the failure can look like overly broad prescribing rights, weak step-up authentication, or poor session handling. In healthcare environments, it is useful to compare the EPCS workflow against broader identity guidance such as the Healthcare Identity Security Guide, because the same control weaknesses that affect clinician access often show up in prescribing paths, shared workstations, and verification gaps.
What the failure means operationally
An EPCS program is not failing just because it has defects. It is failing when those defects allow controlled substance prescribing to happen outside the intended trust model. If policy says a check is mandatory, but the system or workflow makes it optional in practice, the organisation has a governance problem as well as a technical one.
The consequence is twofold. First, compliance claims become unreliable because the organisation cannot prove the control is consistently applied. Second, the programme weakens deterrence, because users learn that the path of least resistance is also the path they can use to get work done. That erodes both security posture and process discipline.
For controls and audit design, the right question is whether the system can prove enforcement, not just whether the rule exists. A well-run EPCS program should leave enough evidence to show that the prescribed checks were completed, exceptions were rare and justified, and bypasses were not silently becoming the norm.
Risk and Threat Considerations
When EPCS controls are weak, the risk is not only process noncompliance, it is unauthorized or unverified prescribing of controlled substances. The threat surface expands when attackers, insiders, or careless users can exploit weak verification, shared access, or poorly designed exceptions to make prescription activity look legitimate.
Failure mechanism: Control failure usually occurs when policy is separated from workflow enforcement, so the system allows prescriptions to proceed even when required verification steps are skipped, bypassed, or inconsistently applied.
Impact: That can create uncontrolled prescribing, reduce audit confidence, and make it harder to detect whether a prescription was issued through a valid clinical decision or a broken control path.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 sets the technical controls, while ISO/IEC 27001:2022 defines the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | IA-2 — Identification and Authentication (Organizational Users) | EPCS failure often involves broken clinician verification and bypassed login checks. |
| IA-5 — Authenticator Management | EPCS workflows depend on managing credentials and authenticators used for prescription signing. | |
| AU-2 — Event Logging | EPCS programs need evidence of who prescribed, approved, and completed each required step. | |
| Recommendation — Enforce organizational-user authentication before signing controlled prescriptions. Control authenticator lifecycle so signing credentials cannot be bypassed or misused. Log prescription and verification events to prove control enforcement. | ||
| ISO/IEC 27001:2022 | A.5.15 — Access control | EPCS failure is often an access-control failure where required checks are not enforced. |
| A.8.5 — Secure authentication | EPCS depends on reliable authentication before controlled substances can be prescribed. | |
| Recommendation — Define and enforce access rules for prescription signing paths. Require secure authentication for each controlled-substance prescribing action. | ||
Practitioner Guidance
What to verify: Test the actual prescribing path end to end, including exception handling, shared workstation use, and any step that can be skipped without a clear denial. The question is not whether the policy exists, but whether the system can enforce it under real clinical conditions.
Common mistake: Treating high user frustration as mere change management. If users routinely work around the control, that is a signal to redesign the workflow and review the underlying access or verification model, not just to retrain staff.
What good looks like: The intended EPCS path is the easiest reliable path, bypasses are rare and visible, and every completed prescription leaves a clear trace of who did what, when, and under which verification state.
Practitioner takeaway: An EPCS program is healthy when enforcement and usability reinforce each other; if clinicians can complete the task only by side-stepping the control, the program is already failing in practice.
Related resources from NHI Mgmt Group
- What are the signs that an IAM program is failing in practice?
- What are the signs that a mobile DevSecOps program is failing in practice?
- What are the signs that an application security program is failing to stop malicious code in practice?
- What are the signs that a TLS fingerprinting program is failing in practice?
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on September 28, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
